Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 05, 2020 | May 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 05, 2020 · Filed May 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,052 |
Reported balance
After 2020-05-05 transaction · row 1
1 source rowRow 1 · 2020-05-05 · Exercise / conversion · Acquired 2,270 · Balance 129,052 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-05 · Exercise / conversion · Disposed 2,270 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: 100% of the restricted stock units vested on May 5, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: 100% of the restricted stock units vested on May 5, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2004 Filed Nov 23, 2004 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $17.16 | $171,625.00 |
DisclosureSEC source: 0001179110-04-021996 · edgar.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2004 Filed Nov 23, 2004 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,800 | $16.25 | $175,446.00 |
DisclosureSEC source: 0001179110-04-021996 · edgar.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: All shares and dollar amounts reflect a two-for-one split effected on Sepetmber 3, 2004 benefitting all shareholders of record on August 12, 2004. Read SEC document |
| July 01, 2004 Filed Jul 6, 2004 20:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 522.39 | $67.00 Strike: $67.00 | $35,000.13 |
DisclosureSEC source: 0001179110-04-014347 · edgar.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522.39 Underlying: Common Stock · 522.39 shares Expires not disclosed F1 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock over five years when the reporting personreaches the age of 65. F1 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock over five years when the reporting personreaches the age of 65. Read SEC document |
| May 25, 2004 Filed May 27, 2004 23:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $62.80 | $0.00 |
DisclosureSEC source: 0001179110-04-011740 · edgar.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2014-05-25 F1 · derivative.exercise_date: Options vest 100% on date of grant. Read SEC document |
| April 21, 2004 Filed Apr 23, 2004 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $57.00 | $0.00 |
DisclosureSEC source: 0001179110-04-008755 · edgar.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2014-04-21 Read SEC document |
| October 25, 2003 Filed Oct 28, 2003 21:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $58.41 | $0.00 |
DisclosureSEC source: 0001179110-03-009395 · edgar.xml · derivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2013-10-25 F2 · derivative.exercise_date: Options vest 100% on the first anniversary date of the grant, provided there is no interruption of service prior to vest date. Should service terminate within the year, vesting will be quarterly from date of grant. F1 · derivative.underlying_shares: Granted pursuant to the Gilead Sciences, Inc. 1995 Non-Employee Directors' Stock Option Plan in a transaction exempt from Rule 16b-3. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,800 | $0.00 Strike: $32.49 | $0.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · derivative · entry 8 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 1,800 shares Expires 2012-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted pursuant to the Gilead Sciences, Inc. 1995 Directors' Stock Option Plan in a transction exempt from Rule 16b-3. F2 · derivative.exercise_date: Options vest in equal quarterly installments over a five year period, beginning from date of grant. F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,200 | $0.00 Strike: $34.33 | $0.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · derivative · entry 7 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,800 Underlying: Common Stock · 31,200 shares Expires 2011-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted pursuant to the Gilead Sciences, Inc. 1995 Directors' Stock Option Plan in a transction exempt from Rule 16b-3. F2 · derivative.exercise_date: Options vest in equal quarterly installments over a five year period, beginning from date of grant. F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $50.21 | $150,630.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · nonDerivative · entry 6 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $50.17 | $501,700.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · nonDerivative · entry 5 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $50.26 | $502,600.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · nonDerivative · entry 4 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $50.27 | $502,700.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · nonDerivative · entry 3 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,800 | $32.49 | $58,482.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · nonDerivative · entry 2 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| May 29, 2003 Filed May 30, 2003 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 31,200 | $34.33 | $1,070,940.00 |
DisclosureSEC source: 0001179110-03-001393 · edgar.xml · nonDerivative · entry 1 WILSON GAYLE E · CIK 0001198227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.